Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3397
- Registration Number
- NCT00079274
- Locations
- 🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
🇫🇷Hopital Claude Gallien, Quincy Sous Senart, France
🇫🇷Hopital Saint Antoine, Paris, France
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT00022178
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 18
- Registration Number
- NCT00006037
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 4
- Registration Number
- NCT00006472
- Locations
- 🇺🇸
Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005791
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00007878
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00020917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00008281
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸Medical Oncology Internal Medicine, Los Angeles, California, United States
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 36
- Registration Number
- NCT00003582
- Locations
- 🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.